Hospital Injectable Products · LP-188
Heparin sodium Injection
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-188Hospital Injectable Products
- Generic identity
- Heparin sodiumInjection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-188
- Generic ingredient
- Heparin sodium
- Dosage form
- Injection
- Proposed strength
- 5,000 IU/mL (25,000 IU per 5 mL vial)
- Proposed pack
- Vial; carton 10 vials
- Portfolio category
- Hospital Injectable Products
About Heparin sodium
Heparin sodium is an anticoagulant used to reduce blood-clot formation in defined clinical settings. It acts through antithrombin and related coagulation pathways. It is not interchangeable with low-molecular-weight heparins or with a dilute catheter-flush solution solely because the names share heparin. Concentration and activity units must be communicated clearly because selection errors can produce serious bleeding or inadequate anticoagulation.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Professional assessment considers the reason for anticoagulation, bleeding risk, platelet history and the required monitoring approach. Hospital use may involve prevention or treatment of thrombosis or another protocol-specific indication. A catalogue entry cannot determine the route or laboratory target for an individual patient. The source lists activity per millilitre and total vial activity; these are different descriptions of the presentation and are not dosing instructions.
Important safety considerations
Bleeding is a principal risk. Heparin-induced thrombocytopenia can occur and may be associated with thrombosis despite a low platelet count. Previous heparin-related reactions, active bleeding, recent procedures and concomitant antiplatelet or anticoagulant medicines require review. Longer exposure can affect bone and electrolyte balance. New bleeding, unusual bruising or symptoms of thrombosis need assessment. Intramuscular administration is not appropriate for heparin anticoagulation products.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The 5,000 IU/mL and 25,000 IU/5 mL specifications require explicit units and container identification. Confirm preservative content, single- versus multi-dose status and the exact authorized route. Do not present this concentration as a catheter flush.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm anticoagulation indication, bleeding and platelet risks, concurrent therapies and monitoring. Verify activity units and concentration independently before preparation or administration.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Heparin sodium
- Dosage form / presentation
- Injection
- Catalogue strength
- 5,000 IU/mL; 25,000 IU/5 mL
- Catalogue pack
- Vial; carton 10 vials
- Portfolio category
- Hospital Injectable Products
Layer 02
Unresolved product-specific fields
- P020 — “5,000 IU/mL” and “25,000 IU/5 mL” may describe the same concentration/presentation, but the catalogue does not establish whether they are duplicate expressions or distinct SKUs. They remain separate source expressions pending confirmation.
- Single- versus multidose status, preservative content, authorised route and whether any presentation is intended as a catheter flush require exact product evidence.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Heparin Injectiongovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled presentation matrix confirming whether the concentration and total-content/fill-volume expressions describe one presentation or distinct SKUs, without duplicate counting.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-188, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-188.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.